# Pleural Effusion Thoracentesis Indications

Perform diagnostic thoracentesis for a safely accessible effusion without a clear systemic cause, especially when infection, malignancy, or another exudative process is possible. Use ultrasound to establish procedural feasibility, obtain paired serum studies, and let fluid pH, microbiology, and cytology determine urgent drainage or tissue diagnosis.

**Clinical question:** Which adults with pleural effusion need thoracentesis, and which fluid findings require drainage or further invasive evaluation?

Updated: 2026-09-15T18:10:36.164691+00:00

## What matters in practice
- Diagnostic thoracentesis is generally indicated for a pleural effusion that is safely accessible and lacks an obvious systemic transudative cause; exceptions include fluid too small to safely sample, small ipsilateral effusion with pulmonary embolism, and an apparent transudate from decompensated heart, liver, or end-stage renal failure. [4]
- At diagnostic thoracentesis, send pleural protein and LDH with paired serum protein and LDH, plus pH, glucose, cell count with differential, Gram stain/culture, and cytology when malignancy is suspected. [18][20][21]
- Frank pus, positive Gram stain or culture, pleural pH below 7.20, glucose below 60 mg/dL, or loculation with pneumonia identifies a complicated parapneumonic process for which antibiotics alone are insufficient and pleural drainage is required. [19][21][23]
- Negative cytology does not exclude malignant pleural effusion: first-sample sensitivity is approximately 60%; if suspicion remains high after two negative thoracenteses, proceed to medical thoracoscopy with pleural biopsy. [6][18]
- Use thoracic ultrasound to determine whether there is adequate fluid for safe sampling and to guide thoracentesis, chest-tube insertion, and transcutaneous pleural biopsy. [7][19]

## Who should undergo diagnostic thoracentesis?

Base the decision on procedural accessibility, clinical context, and whether fluid analysis will change management.

Perform diagnostic thoracentesis when a pleural effusion is safely accessible and the cause is uncertain, particularly when infection, malignancy, tuberculosis, autoimmune pleuritis, chylothorax, hemothorax, or another exudative process is plausible. Pleural fluid analysis is the central diagnostic test for separating transudative from exudative physiology and directing etiology-specific testing. [4][18][21]

Defer diagnostic sampling when the effusion is too small to safely access, defined in one review as less than 1 cm in depth on imaging. A small ipsilateral effusion accompanying pulmonary embolism may also be observed rather than sampled. In patients with an obvious systemic transudative setting—decompensated heart failure, decompensated liver failure, or end-stage renal failure—initial cause-directed management without thoracentesis is reasonable unless the presentation becomes atypical or diagnostic uncertainty persists. [4]

Use thoracic ultrasound before the procedure to confirm a safe fluid target and to identify procedural barriers. Ultrasound is also useful during thoracentesis, chest-tube placement, and percutaneous pleural biopsy. [7][19]
- Sample an effusion when a new unilateral, unexplained, or clinically atypical collection could represent infection, malignancy, or another local pleural disorder. [4][18]
- Do not rely on the appearance of a presumed heart-failure effusion alone when clinical features suggest a competing exudative cause; Light criteria can classify 25% to 30% of heart-failure transudates as exudates, requiring interpretation in the clinical context. [18]
- Diagnostic aspiration typically requires only 20 to 30 mL of pleural fluid. [21]

*Initial procedural decision for pleural effusion evaluation. [4][7][19]*

| Clinical setting | Thoracentesis decision | Immediate next step |
| --- | --- | --- |
| Safely accessible effusion with uncertain cause | Perform diagnostic thoracentesis. [4][18] | Obtain paired serum and pleural fluid studies. [18][20] |
| Effusion less than 1 cm deep on imaging | Do not sample if unsafe. [4] | Use imaging and clinical follow-up; reassess if fluid enlarges. [4] |
| Obvious decompensated heart, liver, or end-stage renal failure | Initial thoracentesis may be deferred. [4] | Treat the systemic disorder; sample if the course is atypical or uncertainty remains. [4][18] |
| Small ipsilateral effusion with pulmonary embolism | Thoracentesis may be deferred. [4] | Manage pulmonary embolism and reassess the pleural collection. [4] |

## What tests should be sent with diagnostic thoracentesis?

Order the core panel at the initial procedure; add targeted studies only when the clinical branch warrants them.

Obtain pleural total protein and LDH together with serum total protein and LDH drawn at the time of thoracentesis so that Light criteria can classify the effusion. A pleural effusion is exudative when at least one criterion is met: pleural-to-serum protein ratio greater than 0.5, pleural-to-serum LDH ratio greater than 0.6, or pleural LDH greater than two-thirds the upper limit of normal serum LDH. [18][22]

Send pleural pH, glucose, cell count with differential, Gram stain, bacterial culture, and cytology as the standard diagnostic panel. Pleural pH and glucose should be prioritized in any parapneumonic effusion because they identify infection requiring drainage even when cultures are negative. [18][20][21]

Use the cell differential as a differential-narrowing test rather than a stand-alone diagnosis. A neutrophil proportion greater than 50% is common in parapneumonic effusions, although approximately 10% of tuberculous effusions may also be neutrophil predominant. Lymphocyte-predominant effusions occur most often with tuberculosis, malignancy, and congestive cardiac failure; lymphoma, post-coronary bypass status, renal or liver failure, rheumatoid arthritis, and chylothorax are additional considerations. [20]

Add cytology when malignant pleural effusion is suspected. Add tuberculosis-directed testing according to individual risk factors and regional prevalence. Low glucose is not specific for infection: values below 60 mg/dL also occur with malignancy, tuberculosis, and rheumatoid pleuritis. [21][22]
- Interpret LDH as an inflammatory marker: pleural LDH greater than three times the serum upper limit of normal, often above 1,000 U/L, supports pleural infection in an appropriate clinical setting but is not specific. [20]
- A pH at or below 7.20 in parapneumonic fluid predicts poor outcome, loculation, and need for invasive drainage. [21][22]
- Frankly purulent fluid establishes empyema regardless of biochemical results. [19][23]

*Core pleural-fluid results and their next clinical action. [18][19][20][21][22]*

| Finding | Interpretation | Action |
| --- | --- | --- |
| Any Light criterion positive | Exudative physiology. [18][22] | Pursue local pleural causes using microbiology, cytology, cell differential, and clinical-imaging correlation. [18][20] |
| pH below 7.20 or glucose below 60 mg/dL with pneumonia | Complicated parapneumonic effusion. [19][21] | Arrange pleural drainage in addition to antimicrobial treatment. [21] |
| Frank pus, positive Gram stain, or positive culture | Pleural infection/empyema. [19][23] | Drain the pleural space; antibiotics alone are insufficient for complicated infection. [21] |
| Neutrophils greater than 50% | Supports parapneumonic effusion but does not exclude tuberculosis. [20] | Integrate with imaging, pH, glucose, microbiology, and epidemiologic risk. [20][21] |
| Lymphocyte-predominant exudate | Consider tuberculosis, malignancy, lymphoma, rheumatoid disease, and chylothorax among other chronic processes. [20] | Order targeted tests and pursue tissue diagnosis when malignancy remains likely. [18][20] |

## When does a parapneumonic effusion require drainage?

The key decision is whether pleural-space infection can resolve with antibiotics alone.

Drain a parapneumonic effusion when fluid is frankly purulent, Gram stain or culture is positive, pH is below 7.20, glucose is below 60 mg/dL, or imaging demonstrates loculation in the setting of pneumonia. These findings identify a complicated parapneumonic effusion or empyema, for which antimicrobial therapy alone is inadequate. Cultures can be negative in up to 40% of fibropurulent-stage infections, so a negative culture must not override the pH, glucose, gross appearance, or imaging pattern. [19][21][23]

Use ultrasound or CT guidance for chest-tube placement when drainage is indicated. Obtain imaging within 24 hours after tube insertion to document position. The cited review recommends retaining the tube until drainage is below 50 mL/day and the empyema cavity has closed. [24]

For category 3 or 4 parapneumonic effusions, drainage is recommended; fibrinolytics, video-assisted thoracoscopic surgery, or surgery may be considered when less invasive drainage does not achieve source control. Intrapleural fibrinolytic therapy has been studied for loculated infection-related effusions that fail to resolve after 24 hours of simple drainage, including empyema and complicated parapneumonic effusion. [2][24]
- A small parapneumonic effusion less than 10 to 20 mm in depth has a favorable prognosis and does not require drainage in the cited pediatric review; reassess if the collection enlarges or fluid chemistry suggests complicated infection. [15]
- Loculation plus pneumonia is a drainage trigger even if aspirated fluid is not grossly purulent. [2][19][21]
- Select antimicrobials to cover likely pneumonia pathogens in the clinical setting; treatment duration depends on microbiology, extent of lung and pleural disease, clinical response, and adequacy of drainage. [24]

*Drainage escalation for parapneumonic effusion and empyema. [19][21][24]*

| Clinical or pleural-fluid feature | Management implication | Escalation |
| --- | --- | --- |
| Free-flowing, nonpurulent effusion without high-risk biochemical features | Some patients may not require drainage. [24] | Monitor clinically and reassess with imaging and fluid results. [24] |
| pH below 7.20, glucose below 60 mg/dL, positive microbiology, or pus | Complicated pleural infection; drain. [19][21][23] | Place image-guided chest tube and document position within 24 hours. [24] |
| Loculated infected effusion or inadequate response to initial drainage | Source control may remain incomplete. [2][24] | Consider intrapleural fibrinolytic therapy, VATS, or surgery. [2][24] |

## When should thoracentesis be repeated or followed by pleural biopsy?

Use cytology first, but escalate promptly to tissue when repeated fluid studies do not resolve high clinical suspicion.

Perform cytologic examination of pleural fluid when malignant pleural effusion is suspected. Cytology detects malignant cells in approximately 60% of malignant pleural effusions on the initial thoracentesis. [6][18]

If cytology is negative but clinical and imaging suspicion remains high, repeat sampling can increase cumulative diagnostic yield; one review reports up to 90% yield after three samples obtained on separate days. When two successive thoracenteses are negative despite high suspicion, medical thoracoscopy with pleural biopsy is recommended. [18]

Interpret a low pleural pH in malignant effusion as a marker of more extensive pleural tumor involvement, higher likelihood of positive cytology, lower pleurodesis success, and poorer prognosis. A pleural pH at or below 7.30 has also been associated with poorer response to chemical pleurodesis. [3][22]
- Do not accept negative initial cytology as exclusion of malignancy when there is no alternative cause of an exudative effusion. [6][18]
- Use ultrasound guidance for transcutaneous pleural biopsy when a percutaneous tissue approach is selected. [7]
- Classify an exudative effusion as malignant when malignancy is established by cytology, flow cytometry, histology, or known cancer without another cause of the effusion. [19]

*Diagnostic sequence when malignant pleural effusion is suspected. [6][18][19]*

| Step | Test or finding | Next action |
| --- | --- | --- |
| Initial procedure | Thoracentesis with cytology. [18][21] | If malignant cells are identified, establish malignant pleural involvement. [6][19] |
| Negative initial cytology | Persistent clinical suspicion. [18] | Repeat thoracentesis for cytology; yield can increase with serial samples. [18] |
| Two negative thoracenteses | High suspicion remains. [18] | Proceed to medical thoracoscopy with pleural biopsy. [18] |

## When is therapeutic thoracentesis appropriate?

Use therapeutic drainage to relieve symptoms from an effusion while preserving diagnostic yield when etiology remains uncertain.

Therapeutic thoracentesis is indicated when pleural fluid removal is needed for symptom relief and can also establish etiology through fluid analysis. For an unexplained symptomatic effusion, send the diagnostic panel during the therapeutic procedure rather than treating the aspiration as purely palliative. [21]

When infection is suspected, simple aspiration is not definitive source control if fluid meets complicated parapneumonic or empyema criteria. Transition to image-guided chest-tube drainage rather than relying on repeated thoracentesis when pH is below 7.20, glucose is below 60 mg/dL, microbiology is positive, pus is present, or the collection is loculated. [19][21][24]

Mild coagulation abnormalities do not necessarily preclude simple thoracentesis, but procedural suitability depends on the patient's ability to cooperate with breathing instructions and on ultrasound-defined safety. [8][19]
- Use ultrasound to identify adequate volume and procedural safety before therapeutic aspiration. [19]
- Obtain diagnostic pleural studies whenever the cause remains uncertain. [18][21]
- Do not substitute serial aspiration for drainage in a biochemically complicated or loculated pleural infection. [19][21][24]

*Therapeutic aspiration versus definitive drainage. [19][21][24]*

| Situation | Role of thoracentesis | Required next step |
| --- | --- | --- |
| Symptomatic, noninfected effusion with uncertain cause | Therapeutic and diagnostic aspiration. [21] | Interpret fluid studies and treat the identified cause. [18][20] |
| Frank pus or positive microbiology | Aspiration establishes diagnosis but is not sufficient treatment. [19][21] | Image-guided chest-tube drainage plus antimicrobials. [24] |
| Low pH or glucose, or loculated parapneumonic fluid | Aspiration identifies complicated infection. [19][21] | Drain pleural space; escalate if drainage fails. [2][24] |

## References
1. Thorax - The BMJ — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/78/Suppl_3.toc.pdf
2. Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions ... — bmjopen.bmj.com — http://bmjopen.bmj.com/content/bmjopen/3/2/e001887.full.pdf
3. Pleura Effusion - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pleura-effusion
4. Pleural Fluid Analysis: Maximizing Diagnostic Yield in the Pleural Effusion Evaluation — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0012369225006944
5. Diagnostic Accuracy of Thoracic Ultrasonography to Differentiate Transudative From Exudative Pleural Effusion - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0012369220304657
6. Malignant Pleural Effusion: Palliative Managements and Indication ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/jso.28156
7. New insights in the use of pleural ultrasonography for diagnosis and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/crj.12907
8. Interventional radiology of pleural diseases - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/j.1440-1843.2011.01948.x
9. Clinical Vignettes - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1525-1497.18.s1.20.x
10. The Evaluation of Pleural Effusion - CHEST Journal — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(16)33373-6/fulltext
11. Pleural Fluid Analysis : Chest — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(25)00694-4/pdf
12. SUBJECT INDEX Volume 125 (JANUARY–JUNE ... - CHEST Journal — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(16)59037-0/pdf
13. Pleural Effusions and Pneumothoraces | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/38/4/170/35019/Pleural-Effusions-and-Pneumothoraces
14. Clinical Approach to a Pleural Effusion - Chest Journal — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(25)05802-7/abstract
15. Pleural Effusion | Pediatrics In Review — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/33/1/45/34661/Pleural-Effusion
16. Neonatal Hypoglycemia - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/issue-pdf/825444
17. Pulmonary Imaging — publications.aap.org — https://publications.aap.org/aapbooks/edited-volume/chapter-pdf/1591657/ch7.pdf
18. Pleural Effusion - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK448189
19. The Use of Thoracic Ultrasound to Predict Transudative and Exudative Pleural Effusion — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9979869
20. Interpreting pleural fluid results  - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6542220
21. Thoracentesis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441866
22. Diagnostic Tools of Pleural Effusion — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4050067
23. Pleural effusion: diagnosis, treatment, and management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4753987
24. Parapneumonic Pleural Effusions and Empyema Thoracis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK534297

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.